Results 31 to 40 of about 107,234 (254)
Rational design of novel phenol ether derivatives as non-covalent proteasome inhibitors through 3D-QSAR, molecular docking and ADMET prediction [PDF]
Exploration of Drug Science, 2023 Aim: The purpose of this paper is to use different structures and ligand-based drug design methods properly to provide theoretical guidance for the design of novel non-covalent proteasome inhibitors, and conduct theoretical analysis of the binding ...
Miao Yuan +4 more
doaj +1 more source
Chemical proteasome inhibition as a novel animal model of inner retinal degeneration in rats.
PLoS ONE, 2019 Chemical proteasome inhibition has been a valuable animal model of neurodegeneration to uncover roles for the ubiquitin-proteasome system in the central nervous system.
Masaaki Kageyama +4 more
doaj +1 more source
Marine Drugs, 2018 The ubiquitin-proteasome system (UPS) is a major proteolytic pathway that safeguards protein homeostasis. The main 26S proteasome consists of a 20S catalytic core proteasome and a 19S substrate recognition proteasome.
Xue-Hua Ling +4 more
doaj +1 more source
The Proteasome Activator PA200/PSME4: An Emerging New Player in Health and Disease
Biomolecules, 2022 Proteasomes comprise a family of proteasomal complexes essential for maintaining protein homeostasis. Accordingly, proteasomes represent promising therapeutic targets in multiple human diseases.
Ayse Seda Yazgili +2 more
doaj +1 more source
Proteasome Inhibitors in Waldenström Macroglobulinemia
Hematology/Oncology Clinics of North America, 2018 Waldenström macroglobulinemia (WM) remains an incurable B-cell lymphoproliferative disorder, yet therapy is only considered for patients with symptomatic disease. Primary therapy options for WM include combinations based on anti-CD20 monoclonal antibodies, mainly rituximab. However, proteasome inhibitors have become an important part of WM therapy both
Kastritis, Efstathios +1 more
openaire +5 more sources
Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
Pharmaceuticals, 2014 Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the treatment of MM has led to significant improvements in outcomes.
Noah M. Merin, Kevin R. Kelly
doaj +1 more source
Proteasome inhibitors for multiple myeloma [PDF]
Japanese Journal of Clinical Oncology, 2018 Therapeutic strategies for multiple myeloma have dramatically changed in the last two decades, especially after the introduction of proteasome inhibitors. The first-in-class proteasome inhibitor, bortezomib, was approved by the US Food and Drug Administration in 2003.
Kiyoshi, Okazuka, Tadao, Ishida
openaire +2 more sources
The ubiquitin‐proteasome system and autophagy as guardians of the cellular proteome
FEBS Letters, EarlyView.This Perspective covers the three principles governing the crosstalk between the ubiquitin‐proteasome system and autophagy in cellular proteostasis: (1) a shared ubiquitin code routing substrates via shuttle factors or autophagy receptors; (2) spatial compartmentalization into phase‐separated degradation hubs and organelle‐specific modules (exemplified
Ivan Dikic
wiley +1 more source
FEBS Letters, EarlyView.Proteostasis and the gut microbiota play a key role in shaping host physiology. Microbiota‐derived metabolites, vitamins, and RNA modulate host proteostasis. Findings from model systems, including C. elegans, indicate microbes can either stabilize or disrupt host proteostasis.
Abhishek Anil Dubey, Maria Ermolaeva
wiley +1 more source
BMC Cancer, 2011 Background Targeting the ubiquitin-proteasome pathway is a promising approach for anticancer strategies. Recently, we found Bik accumulation in cancer cell lines after they were treated with bortezomib.
Zhou Wei +6 more
doaj +1 more source